Implementation of Pre-emptive Pharmacogenomics Testing in Singapore-based Private Hospital Institutions (IMPT Study)

NCT05504135 | Completed

• 1 other identifier: SG-RMG-01-20190401
• Study Type: observational
• Target: 222
• Locations: 1 country
• Sites: 1

Brief Summary

In collaboration with Raffles Medical Group, we will be recruiting 500 patients and following them for the next 3-12 months to see whether pharmacogenomics information provided in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.

Conditions

Pre-emptive Pharmacogenomics

Outcome Measures

Primary Outcomes (8)

• Turnaround time of genotype result, compared to expected

  6 months

• Overall satisfaction of patient

  Via survey upon recruitment

  0 months

• Overall satisfaction of patient

  Via survey at month 3 of the study

  3 month

• Overall satisfaction of patient

  Via survey at month 12 of the study

  12 months

• Overall satisfaction of site principal investigators

  Via survey done at month 6 of the study

  6 months

• Overall satisfaction of prescribing physicians

  Via survey done at month 12 of the study

  12 months

• Prevalence of clinically actionable genotypes

  The number of patients receiving recommendations that includes a certain follow up action which includes monitoring, change of dosing or change of prescription.

  12 months

• Recommendation acceptance rate

  Defined by: (1) Number of physicians who are interested to consider pharmacogenomics information to guide prescription, measured by click-through rate of Pharmacogenomics Access Button; (2) Number of changes made to the medications post-PGx testing; (3) Data obtained from satisfaction survey for prescribing physicians

  12 months

Study Arms (1)

RMG Patients

Diagnostic Test: Pharmacogenomics Testing

Interventions

Pharmacogenomics Testing DIAGNOSTIC_TEST

To test if pharmacogenomics information (produced from testing) included by us in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.

RMG Patients

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

250 patients visiting Raffles Hospital in Singapore

You may qualify if:

• Patients who experienced at least one of the following diseases, or is at risk of developing them:
• Diabetes Mellitus
• Hypertension
• Hyperlipidaemia
• Ischaemic Heart Disease
• Stroke
• Osteoarthritis
• Rheumatoid Arthritis
• Gout
• Anxiety
• Major Depression

You may not qualify if:

• Below ages 21 and above ages 65

Sponsors & Collaborators

• Nalagenetics Pte Ltd: lead

Study Sites (1)

Raffles Hospital

Singapore, Singapore, 188770, Singapore

Location

Related Publications (1)

• Ng FF, Verma R, Sani L, Irwanto A, Lee M, Wee A, Chng SK, Wong M, Chan A. A feasibility study on implementing pre-emptive pharmacogenomics testing in outpatient clinics in Singapore (IMPT study). Pharmacogenomics J. 2025 Mar 12;25(1-2):7. doi: 10.1038/s41397-025-00366-1.

  PMID: 40074758 DERIVED

Study Officials

• Melvin Wong, Dr

  Raffles Medical Group

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 11, 2022
• First Posted: August 17, 2022
• Study Start: October 3, 2022
• Primary Completion: August 31, 2023
• Study Completion: August 31, 2024
• Last Updated: May 30, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

SG (1)